Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0N4HQ
|
|||
| Former ID |
DNCL002273
|
|||
| Drug Name |
OXi4503
|
|||
| Synonyms |
OXi4503; Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Acute myelogenous leukaemia [ICD-11: 2A41; ICD-10: C92.2] | Phase 1/2 | [1] | |
| Acute myeloid leukaemia [ICD-11: 2A60] | Phase 1/2 | [2] | ||
| Myelodysplastic malignancy [ICD-11: 2A44; ICD-10: C94.6] | Phase 1/2 | [2] | ||
| Company |
OXiGENE South
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C18H18Na4O12P2
|
|||
| Canonical SMILES |
COC1=C(C(=C(C=C1)C=CC2=CC(=C(C(=C2)OC)OC)OC)OP(=O)([O-])[O-])OP(=O)([O-])[O-].[Na+].[Na+].[Na+].[Na+]
|
|||
| InChI |
1S/C18H22O12P2.4Na/c1-25-13-8-7-12(16(29-31(19,20)21)18(13)30-32(22,23)24)6-5-11-9-14(26-2)17(28-4)15(10-11)27-3;;;;/h5-10H,1-4H3,(H2,19,20,21)(H2,22,23,24);;;;/q;4*+1/p-4/b6-5-;;;;
|
|||
| InChIKey |
NRKFVEPAQNCYNJ-YGGCHVFLSA-J
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.